About 1 in 7 US adults starting semaglutide were given an off-label high first dose, and those patients had a 25% higher rate of stopping the drug early and were less likely to still be on it a year later
Aims Little is known about how glucagon-like peptide-1 receptor agonists (GLP-1RA) are initiated in real-world settings and whether prescribing behaviours in routine care contribute to the high disc...